On the Record · Indivior Pharmaceuticals
Indivior Pharmaceuticals acquisitions, on the record
The businesses Indivior Pharmaceuticals bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Opiant Pharmaceuticals, Inc.Word for word“On March 2, 2023, the Group acquired 100% of the share capital of Opiant, which at the time was a publicly traded company in the United States, for upfront cash consideration of $146 million and an additional amount to be potentially paid upon achievement of net sales milestones.” 20-F for 2023 | acquisition | March 2, 2023 | $146 million |
full rights to the patents and other assets underlying INDV-2000 from C4X DiscoveryWord for word“On July 31, 2023, we acquired full rights to the patents and other assets underlying this potential product in exchange for a payment of approximately $20.5 million.” 20-F for 2023 | acquisition | July 31, 2023 | approximately $20.5 million |
an aseptic manufacturing facility in Raleigh, North CarolinaWord for word“On November 1, 2023, the Group acquired an aseptic manufacturing facility in Raleigh, North Carolina for upfront consideration of $5 million in cash and assumption of certain contract manufacturing obligations.” 20-F for 2023 | acquisition | November 1, 2023 | $5 million in cash |
specialty pharmaceutical business unit of RBWord for word“Demerger means the acquisition of the specialty pharmaceutical business unit of RB by Indivior PLC, which became effective on December 23, 2014.” 20-F for 2023 | acquisition | December 23, 2014 | — |
legacy TEMGESIC® (buprenorphine) franchise outside of North AmericaWord for word“Net other operating income in 2021 included $32 million of net exceptional benefits primarily due to the net proceeds received from the sale of the legacy TEMGESIC® (buprenorphine) franchise outside of North America and a Directors' & Officers' insurance claim settlement.” 20-F for 2023 | divestiture | 2021 | — |
aseptic manufacturing facility in the U.S.Word for word“On November 1, 2023, the Company acquired an aseptic manufacturing facility in the U.S. for upfront consideration of $5 million in cash and assumption of certain contract manufacturing obligations.” 10-K for 2024 | acquisition | On November 1, 2023 | $5 million in cash |
Raleigh Manufacturing FacilityWord for word“In connection with our acquisition of the Raleigh Manufacturing Facility, the Company assumed onerous contracts and carries a provision of $6 million.” 10-K for 2024 | agreed acquisition | — | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) |
|---|---|
| 2022-12-31 | $0 |
| 2023-12-31 | $129 million |
| 2024-12-31 | $0 |
| 2025-12-31 | $0 |
Deal filings since 2016
- 2026-08-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2026-03-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2026-01-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-03-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Indivior Pharmaceuticals’s annual reports (10-K for 2025, 10-K for 2024, 20-F for 2023) and the financial data it files with the SEC, as of 2026-02-26. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.